A769662 Inhibits Insulin-Stimulated Akt Activation in Human Macrovascular Endothelial Cells Independent of AMP-Activated Protein Kinase

Anastasiya Strembitska 1, Sarah J. Mancini 1, Jonathan M. Gamwell 1,2, Timothy M. Palmer 1,3, George S. Baillie 1 and Ian P. Salt 1,*

1 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK; a.strembitska.1@research.gla.ac.uk (A.S.); sarah.mancini@glasgow.ac.uk (S.J.M.); jonathan.gamwell@rdm.ox.ac.uk (J.M.G.); tim.palmer@hymss.ac.uk (T.M.P.); george.baillie@glasgow.ac.uk (G.S.B.)
2 Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
3 Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, UK
* Correspondence: ian.salt@glasgow.ac.uk; Tel.: +44-(0)141-330-2049; Fax: +44-(0)141-330-5481

Abstract: Protein kinase B (Akt) is a key enzyme in the insulin signalling cascade, required for insulin-stimulated NO production in endothelial cells (ECs). Previous studies have suggested that AMP-activated protein kinase (AMPK) activation stimulates NO synthesis and enhances insulin-stimulated Akt activation, yet these studies have largely used indirect activators of AMPK. The effects of the allosteric AMPK activator A769662 on insulin signalling and endothelial function was therefore examined in cultured human macrovascular ECs. Surprisingly, A769662 inhibited insulin-stimulated NO synthesis and Akt phosphorylation in human ECs from umbilical veins (HUVECs) and aorta (HAECs). In contrast, the AMPK activators compound 991 and AICAR had no substantial inhibitory effect on insulin-stimulated Akt phosphorylation in ECs. Inhibition of AMPK with SBI-0206965 had no effect on the inhibition of insulin-stimulated Akt phosphorylation by A769662, suggesting the inhibitory action of A769662 is AMPK-independent. A769662 decreased IGF1-stimulated Akt phosphorylation yet had no effect on VEGF-stimulated Akt signalling in HUVECs, suggesting that A769662 attenuates early insulin/IGF1 signalling. The effects of A769662 on insulin-stimulated Akt phosphorylation were specific to human ECs, as no effect was observed in the human cancer cell lines HepG2 or HeLa, as well as in mouse embryonic fibroblasts (MEFs). A769662 inhibited insulin-stimulated Erk1/2 phosphorylation in HAECs and MEFs, an effect that was independent of AMPK in MEFs. Therefore, despite being a potent AMPK activator, A769662 has effects unlikely to be mediated by AMPK in human macrovascular ECs that reduce insulin sensitivity and eNOS activation.

Keywords: AMP-activated protein kinase; protein kinase B; Akt; insulin signalling; A769662; endothelial function

1. Introduction

Endothelial cells (ECs) are essential for modulation of vascular homeostasis and signal transduction [1], including the production and regulation of vascular tone, modulation of inflammatory responses and maintenance of an anti-atherogenic phenotype of vascular smooth muscle cells (VSMCs) [1]. Being the downstream target of phosphoinositide (PI) 3-kinase (PI3K), protein kinase B (Akt) is one of the key kinases regulating cell survival, cell-cycle progression and metabolism [2].
Under physiological conditions, insulin [3], VEGF [4] or IGF1 [5] stimulation rapidly leads to increased Akt activity by increasing Ser473 and Thr308 phosphorylation.

In healthy subjects, insulin acts as a vasodilator, stimulating calcium-independent NO synthesis in cultured human aortic ECs (HAECs) through Akt-mediated phosphorylation of endothelial nitric oxide synthase (eNOS) Ser1177 and Ser615 [6]. However, in murine models of diabetes and people with diabetes, impaired insulin-stimulated blood flow and NO bioavailability have been demonstrated [7]. Decreased NO bioavailability leads to endothelial dysfunction in animal models and human subjects, increasing risk of cardiovascular events and pro-inflammatory signalling in the vasculature [8].

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase sensitive to intracellular AMP levels which acts as a master regulator of energy metabolism [9,10]. AMPK is activated in response to an increase in the intracellular [AMP + ADP]:ATP ratio and simultaneous AMPKα Thr172 phosphorylation by the upstream kinases liver kinase B1 or calcium/calmodulin-dependent protein kinase kinase β [9,10]. Activated AMPK inhibits anabolic processes which consume ATP [9,10], reduces inflammation [11,12], inhibits endothelial cell proliferation [13], stimulates mitochondrial biogenesis [14], and increases insulin sensitivity [9,15], making it an attractive pharmacological target for diabetes and cardiovascular pathologies [10]. There are 12 differentially expressed AMPK isoforms, each composed of catalytic α1/α2, and regulatory β1/β2 and γ1/γ2/γ3 subunits [9,10], allowing a specialised cellular and systemic response to different metabolic stimuli [10].

Previous studies have reported that AMPK activation improved insulin sensitivity and energy homeostasis, and attenuated inflammatory signalling in insulin-sensitive tissues, such as muscle [14], liver [16,17] and adipose tissue [11,18] as well as ECs [12,15]. Several AMPK activators have been shown to increase NO synthesis in HAECs in an AMPK-dependent manner [10]. Nevertheless, it is unclear whether all AMPK activators improve insulin sensitivity and vascular function, as previous studies have largely been conducted using a variety of compounds that activate AMPK by altering cellular nucleotide ratios, including rosiglitazone, resveratrol, metformin and canagliflozin or mimic AMP, such as AICAR (5-amino-4-imidazolecarboxamide ribonucleoside) [12,19–22].

In the last 15 years, there has been considerable effort to develop AMPK-selective small-molecule activators, resulting in the development of A769662 [23], the discovery of salicylate as an AMPK activator and, more recently, the development of compound 991—a compound 5–10-fold more potent than A769662 [24]. A769662 is an allosteric activator that binds complexes containing AMPKβ1, also inhibiting AMPKα Thr172 dephosphorylation [24,25]. Since being first described as an AMPK activator, some AMPK-independent effects of A769662 have been reported [26–29], yet it remains a commonly utilised pharmacological tool for selective AMPK activation. The effects of A769662 on insulin signalling and insulin-stimulated Akt/eNOS axis activation in primary human ECs were therefore determined.

2. Results

2.1. Insulin-Stimulated Signalling and NO Production are Reduced by A769662 in Human Endothelial Cells

Stimulation of HUVECs with concentrations of insulin above 0.1 µM robustly stimulated phosphorylation of Akt at Ser473 and Thr308 (Supplementary Figure S1), similar to concentrations of insulin previously demonstrated to be required for insulin-stimulated NO synthesis in cultured endothelial cells [30]. All subsequent experiments were therefore conducted using 1 µM insulin. To examine the effect of A769662 on HUVEC insulin signalling, cells were preincubated in the presence or absence of A769662 prior to stimulation with insulin and NO synthesis and the extent of Akt phosphorylation assessed. Insulin modestly increased NO synthesis, yet insulin-stimulated NO synthesis was lost upon preincubation with A769662 (Figure 1A).
Figure 1. The effect of A769662 on insulin-stimulated NO production and Akt phosphorylation in HUVECs. (A) HUVECs were stimulated with A769662 (50 µM, 45 min) prior to insulin (1 µM, 15 min), conditioned media collected and NO production assessed. Data (mean ± SEM) shown from three independent replicates. (B–E) HUVECs were stimulated with A769662 (50 µM, 45 min) or AICAR (2 mM, 45 min) prior to insulin (51 µM, 15 min) and cell lysates prepared. Proteins were resolved by SDS-PAGE and immunoblotted with the antibodies indicated. (B) Representative immunoblots from three biological replicates with molecular weight markers indicated. Phospho-Akt Thr308 protein levels were assessed by stripping and re-probing the membranes. Densitometric quantification of (C) ACC, (D) Akt Ser473 and (E) Akt Thr308 phosphorylation normalised to β-tubulin or Akt (mean ± SEM). * p < 0.05, ** p < 0.01, relative to absence of insulin. # p < 0.05, ## p <0.01 relative to absence of AMPK activator.

A769662 (50 µM, 45 min) increased AMPK activity, assessed by immunoblotting of AMPK-specific ACC (acetyl CoA carboxylase) Ser79 phosphorylation (Figure 1B,C), yet insulin had no effect on ACC phosphorylation. The inhibition of NO production was associated with markedly reduced insulin-stimulated phosphorylation of Akt at Ser473 and Thr308 (Figure 1D,E). In contrast, the AMPK activator AICAR, which is converted to the AMP mimetic ZMP in cells, increased basal and insulin-stimulated Akt Ser473 and Thr308 phosphorylation (Figure 1D,E), despite activating AMPK to a similar degree as assessed by ACC Ser79 phosphorylation (Figure 1C). Furthermore, the direct AMPK activator compound 991, which allosterically activates AMPK at the same site as A769662 [31], had no effect on basal or insulin-stimulated Akt Thr308 phosphorylation, and only modestly reduced insulin-stimulated Akt Ser473 phosphorylation by 10% despite activating AMPK to a similar extent (Figure 2).
which has recently been described as a selective inhibitor of AMPK [32]. Preincubation with 30 µM SBI-0206965 completely inhibited A769662-stimulated ACC Ser79 phosphorylation (Figure 4A,B), yet had no effect on the inhibition of insulin-stimulated Akt phosphorylation at Ser473 or Thr308 (Figure 4A,C,D), further indicating that the inhibitory effect of A769662 was AMPK-independent.

Furthermore, the time dependence of the inhibitory effect of A769662 on insulin-stimulated Akt phosphorylation was assessed. A769662 (50 µM) rapidly stimulated ACC phosphorylation in HUVECs within 5 min, an effect that was sustained for at least 2 h (Figure 3E,F). The inhibitory effect of A769662 on insulin-stimulated Akt Ser473 phosphorylation occurred similarly rapidly within 5 min and was sustained for 1 h (Figure 3E,G).

To determine whether the inhibition of insulin-stimulated Akt phosphorylation in ECs was AMPK-dependent, similar experiments were conducted after prior incubation in the SBI-0206965, which has recently been described as a selective inhibitor of AMPK [32]. Preincubation with 30 µM SBI-0206965 completely inhibited A769662-stimulated ACC Ser79 phosphorylation (Figure 4A,B), yet had no effect on the inhibition of insulin-stimulated Akt phosphorylation at Ser473 or Thr308 (Figure 4A,C,D), further indicating that the inhibitory effect of A769662 was AMPK-independent.
Figure 3. A769662 decreases Akt phosphorylation in a concentration- and time-dependent manner in HUVECs. HUVECs were stimulated with (A–D) the indicated concentrations of A769662 for 45 min or (E–G) 50 µM A769662 for the indicated durations prior to insulin (1 µM, 15 min). Cell lysates were prepared and immunoblotted with the antibodies indicated. (A,E) Representative immunoblots from three independent biological replicates with molecular weight markers indicated. Total ACC protein level was assessed by stripping and re-probing the membranes. Densitometric quantification of (B,F) ACC Ser79, (C,G) Akt Ser473 and (D) Akt Thr308 phosphorylation (mean ± SEM). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ relative to absence of insulin. # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ relative to absence of A769662.
Figure 4. SBI-0206965 inhibits A769662-stimulated AMPK activation without altering inhibition of insulin-stimulated Akt phosphorylation in HUVECs. HUVECs were stimulated with A769662 (50 µM, 45 min) prior to insulin (1 µM, 15 min) after preincubation in the presence or absence of SBI-0206965 (SBI, 30 µM, 30 min) and cell lysates prepared. Proteins were resolved by SDS-PAGE and immunoblotted with the antibodies indicated. (A) Representative immunoblots from six biological replicates with molecular weight markers indicated. Densitometric quantification of (B) ACC, (C) Akt Ser473 and (D) Akt Thr308 phosphorylation normalised to total ACC or Akt (mean ± SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to absence of insulin. ##p < 0.01, ###p < 0.001, #### relative to absence of A769662. $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 relative to absence of SBI-0206965.

2.2. Insulin Signalling and Insulin-Stimulated NO Production are Significantly Decreased in A769662-Treated HAECs

To determine whether this inhibition of insulin signalling was conserved in ECs from other regions of the vasculature, insulin-stimulated NO synthesis and signalling were assessed in HAECs. A769662 (50 µM) markedly inhibited insulin-stimulated NO synthesis (Figure 5A), an effect associated with reduced insulin-stimulated phosphorylation of Akt Ser473 (Figure 5B,C). To examine whether insulin signalling through an alternative pathway independent of PI3K was influenced by A769662, insulin-stimulated Erk1/2 phosphorylation was assessed. Intriguingly, A769662 significantly inhibited insulin-stimulated Erk1/2 phosphorylation (Figure 5B,D).

To examine whether the inhibitory action of A769662 on insulin-stimulated Akt phosphorylation was observed in non-endothelial cell lines, similar experiments were conducted in the HeLa tumour and HepG2 hepatoma cell lines. Preincubation with A769662 (50 µM, 45 min) or compound 991 (5 µM, 60 min) significantly increased ACC Ser79 phosphorylation in both HeLa (Supplementary Figure S2) and HepG2 cells (Supplementary Figure S3) to a similar extent. Unlike HUVECs, preincubation with A769662 had no statistically significant effect on basal or insulin-stimulated Akt
Ser473 phosphorylation in either cell line, although the statistical significance of the effect of insulin was lost upon preincubation with A769662 in HeLa cells (Supplementary Figure S2C,D). Compound 991 did not affect insulin-stimulated Akt Ser473 and Thr308 phosphorylation in HepG2 cells (Supplementary Figure S3C,D) yet intriguingly did increase insulin-stimulated Akt Ser473 and Thr308 phosphorylation in HeLa cells (Supplementary Figure S2C,D). The inhibition of insulin-stimulated Akt Ser473 phosphorylation by preincubation with A769662 therefore seems to be restricted to ECs, and it is not observed in insulin-sensitive human cell lines.

2.3. A769662 Inhibits Insulin-Stimulated Erk1/2 Phosphorylation in an AMPK-Independent Manner

To further assess the AMPK-dependence of the inhibition of insulin-stimulated Akt and Erk1/2 phosphorylation by A769662, SV40-immortalised wild-type (WT) or AMPK knockout (KO) mouse embryonic fibroblasts (MEFs) [33] were stimulated with insulin after prior incubation in the presence or

---

**Figure 5.** The effect of A769662 on insulin-stimulated NO synthesis and signalling in HAECs. (A) HAECs were stimulated with the indicated concentrations of A769662 prior to insulin stimulation (1 µM, 15 min). Conditioned media was collected and NO production assessed. (B–D) HAECs were incubated with 50 µM A769662 for 45 min prior to insulin stimulation (1 µM) for the indicated durations. Cell lysates were prepared and immunoblotted with the antibodies indicated. (B) Representative immunoblots from three independent biological replicates with molecular weight markers indicated. (C,D) Densitometric quantification (mean ± SEM) of (C) Akt Ser473 or (D) Erk1 Thr202/Tyr204 phosphorylation normalised to total Akt or Erk1 levels respectively (mean ± SEM). *p < 0.05, **p < 0.01 relative to absence of insulin. #p < 0.05, relative to absence of A769662.
absence of A769662 (Figure 6). A769662 (100 µM, 30 min) robustly stimulated ACC phosphorylation in WT MEFs and ACC phosphorylation was undetectable in KO MEFs (Figure 6A). Insulin stimulated Akt Ser473 and Erk1/2 phosphorylation to a similar extent in cells from either genotype, yet A769662 had no effect on insulin-stimulated Akt Ser473 phosphorylation in either genotype (Figure 6B). In contrast, insulin-stimulated Erk1/2 phosphorylation was significantly inhibited by preincubation with A769662 in cells of either genotype (Figure 6C), indicating an AMPK-independent effect.

![Figure 6](image-url)

**Figure 6.** The effect of A769662 on insulin-stimulated Akt and Erk1/2 phosphorylation in wild-type and AMPK knockout MEFs. Wild-type (WT) and AMPK knockout (KO) MEFs were pre-incubated with A769662 (100 µM, 30 min) prior to insulin stimulation (1 µM, 15 min). Cell lysates were prepared, proteins resolved by SDS-PAGE and immunoblotted with the antibodies indicated. (A) Representative immunoblots from four independent biological replicates with molecular weight markers shown. (B,C) Densitometric quantification of (B) Akt Ser473 or (C) Erk2 Thr202/Tyr204 phosphorylation normalised to total Akt or Erk2 levels respectively (mean ± SEM). **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to absence of insulin. #p < 0.05, ##p < 0.01 relative to absence of A769662.

### 2.4. A769662 Inhibits IGF1-Stimulated Akt Ser473 Phosphorylation but Has No Effect on VEGF Signalling

To examine whether A769662 inhibits Akt phosphorylation in response to growth factors other than insulin in ECs, the effect of A769662 on IGF-1 and VEGF were assessed in HUVECs. VEGF (10 ng/mL, 10 min) stimulated a significant increase in Erk1 Thr202/Tyr204 phosphorylation, yet there was only a trend towards an increase in Akt Ser473 phosphorylation (Figure 7). In contrast, IGF1 (25 ng/mL, 10 min) significantly stimulated Akt Ser473 phosphorylation and tended to increase Erk1 Thr202/Tyr204 phosphorylation (Figure 7). Preincubation with A769662 significantly increased ACC Ser79 phosphorylation (Figure 7B) and modestly inhibited IGF1-stimulated Akt phosphorylation (Figure 7C). Although previous studies from our laboratory have shown VEGF stimulated AMPK activity after 5 min [34,35], stimulation with VEGF for 10 min only tended to increase ACC Ser79 phosphorylation in HUVECs (Figure 7B). This disparity may reflect the difference in incubation time, as in previous studies, VEGF stimulated transient ACC Ser79 phosphorylation that reached a maximum at 5 min and decreased rapidly after this point [34]. Furthermore, in contrast to the inhibitory
action of A769662 on insulin-stimulated Erk1/2 phosphorylation observed in HAECs (Figure 5), IGF-1 significantly stimulated Erk1/2 phosphorylation only in the presence of A769662 (Figure 7D).

Figure 7. A769662 tends to attenuate IGF1-stimulated Ser473 Akt phosphorylation but has no effect on VEGF signalling in HUVECs. HUVECs were stimulated with A769662 (50 µM 45 min) prior to VEGF (10 ng/mL, 10 min) or IGF1 (25 ng/mL, 10 min). Cell lysates were prepared, proteins resolved by SDS-PAGE and immunoblotted with the antibodies indicated. (A) Representative immunoblots from four independent biological replicates with molecular weight markers indicated. Total ACC protein level was assessed by stripping and re-probing the membranes. (B–D) Densitometric quantification of (B) ACC Ser79, (C) Akt Ser473 or (D) Erk1 Thr202/Tyr204 phosphorylation normalised to total ACC, Akt or α-tubulin levels respectively (mean ± SEM). * p < 0.05, ** p < 0.01, *** p < 0.001 relative to absence of IGF1/VEGF. # p < 0.05, #### p < 0.0001 relative to absence of A769662.

2.5. AMPK Complexes Containing α1 and β1 Isoforms Contribute the Majority of Total Cellular AMPK Activity in HAECs

A769662 and compound 991 selectively activate AMPK complexes containing the β1 regulatory subunit [31]. It has previously been demonstrated that HepG2 cells principally express AMPKβ1, whereas HeLa cells express both AMPKβ1 and AMPKβ2 [36], yet the proportion of AMPKβ1/β2 complexes in endothelial cells has not been reported. The activities of AMPK complexes containing specific AMPKβ and α isoforms was therefore assessed in HAECs. Complexes containing AMPKβ1 accounted for approximately 60% of the total cellular AMPK activity and AMPKβ2 the remaining 40% in HAECs. As previously reported, complexes containing AMPKα1 represent the majority (~95%) of total cellular AMPK activity in HAECs [21] (Figure 8).
Although IGF1 has a higher affinity for IGF1R, IGF1 may still bind IR and vice-versa. This may explain why A769662 seems to have a more modest effect on IGF1-stimulated Akt Ser473 phosphorylation, although IGF1 has a higher affinity for IGF1R, IGF1 may still bind IR and vice-versa. This may explain why A769662 stimulates activating eNOS Ser1177 phosphorylation in hearts and AICAR and resveratrol phosphorylation. Insulin and IGF1 both activate Akt [49], differing only in the initial step, as they promote proliferation [13,32] and proinflammatory signalling [12,42] in human ECs. Furthermore, compound 991 has been also reported to inhibit proinflammatory signalling in ECs [12].

It is, therefore, surprising that A769662 inhibited insulin-stimulated NO synthesis in HUVECs and HAECs, as many studies report that AMPK activation stimulates NO synthesis [10]. Indeed, A769662 stimulates activating eNOS Ser1177 phosphorylation in hearts and AICAR and resveratrol have been reported to improve impaired insulin-mediated vascular responses in rodents [43–45]. Endothelial AMPK activation is not always associated with eNOS phosphorylation or NO synthesis, however [46,47], and the lack of insulin-stimulated NO synthesis in A769662-stimulated HAECs and HUVECs is likely to be a consequence of reduced insulin-stimulated Akt phosphorylation, since Akt is required for the activation of eNOS by insulin [48]. A769662 also decreased IGF1-stimulated Akt phosphorylation. Insulin and IGF1 both activate Akt [49], differing only in the initial step, as they bind to the insulin receptor (IR) and IGF1 receptor (IGF1R) respectively. In addition, IGF1R and IR share enough structural similarity to allow interchangeable binding of IGF1 and insulin [49,50]. Although IGF1 has a higher affinity for IGF1R, IGF1 may still bind IR and vice-versa. This may explain why A769662 seems to have a more modest effect on IGF1-stimulated Akt Ser473 phosphorylation, as IGF1 signalling may recruit distinct populations of IR substrate (IRS) proteins compared to insulin [51]. On the other hand, unlike insulin and IGF1, VEGF signalling does not utilise IRSs...
to recruit PI3K and was unaffected by A769662 preincubation [52]. As both Akt Ser473 and Thr308 phosphorylation were inhibited by A769662 in ECs, this suggests that A769662 does not simply inhibit the kinases that phosphorylate those sites, mammalian target of rapamycin complex 2 (mTORC2) or phosphoinositide-dependent protein kinase-1 (PDK1) respectively [2]. In addition, A769662 also inhibited insulin-stimulated Erk1/2 phosphorylation in ECs and MEFs, which is activated by a pathway separate to that of Akt after insulin receptor activation [53]. Importantly, A769662 also inhibited insulin-stimulated Erk1/2 phosphorylation in MEFs lacking AMPK, demonstrating that this effect is AMPK-independent. A769662 has previously been demonstrated to have no direct effect on the activity of Akt or PDK1, although it did inhibit the Erk1 kinase, mitogen-activated protein kinase kinase-1 (MKK1), in vitro [54]. In contrast, IGF-1-stimulated Erk1 phosphorylation was accentuated by A769662 in HUVECs, such that direct inhibition of MKK1 by A769662 may not simply underlie the inhibition of insulin-stimulated Erk1/2 phosphorylation. Taken together, these data indicate that A769662 inhibits at the level of the insulin/IGF-1 receptor or a receptor-associated protein, thereby inhibiting both pathways.

The inhibition of insulin-stimulated Akt phosphorylation by A769662 in ECs was not recapitulated by either compound 991 or AICAR, both of which activate AMPK to a similar degree. Compound 991 allosterically activates AMPK at a similar site to A769662 [31], whereas AICAR is phosphorylated to the AMP-mimetic, ZMP within cells [39]. Indeed, AICAR increased basal and insulin-stimulated Akt phosphorylation in ECs, in agreement with previous reports [15,21]. As both Akt Ser473 and Thr308 phosphorylation increased, this likely reflects stimulation of PI3K or earlier signalling events by AICAR, independent of AMPK activation. Given that the inhibition of Akt phosphorylation was still observed in ECs in which AMPK activity had been completely inhibited by SBI-0206965 and the lack of effect of compound 991 despite the similar mechanism by which compound 991 activates AMPK, these data indicate an AMPK-independent action of A769662 on insulin-stimulated Akt phosphorylation, although it occurs with a similar concentration to that required for AMPK activation.

Intriguingly, the inhibitory effect of A769662 on insulin-stimulated Akt activation was limited to ECs, as it was not observed in MEFs, HeLa or HepG2 cells, although the statistical significance of stimulation by insulin was lost in HeLa cells preincubated with A769662. A769662 (100 µM) has been demonstrated previously to inhibit basal Akt Ser473 phosphorylation in prostate cancer cell lines, yet stimulated Akt Ser473 phosphorylation at a lower concentration (50 µM) [55]. Indeed, previous studies have shown no effect of A769662 on insulin-stimulated Akt activation in rat adult cardiomyocytes, human myotubes or L6 cells [29,56,57]. In contrast to this neutral effect reported in striated muscle cells, A769662 has also been reported to stimulate glucose uptake in muscle cells by increasing PI3K association with IRS1, suggesting an AMPK-independent effect that increased Akt activity [58]. In addition, high concentrations of A769662 stimulated Akt phosphorylation in a manner sensitive to the PI3K inhibitor, wortmannin in CHO cells expressing the δ-opioid receptor [59]. It is clear, therefore, that A769662 influences Akt differentially in different cell types, providing further evidence that these effects are not mediated by AMPK.

In addition, we demonstrate that preincubation of HeLa cells, but not HepG2 cells or ECs, with compound 991 increased insulin-stimulated Akt phosphorylation. These data argue for a cell-type specific/selective effect of A769662 on insulin signalling, whereby only A769662 markedly reduces insulin signalling in ECs and insulin-stimulated Erk1/2 phosphorylation in ECs and MEFs. This cell-type selectivity could be related to differential expression of IR/IGF1R between cell types. HUVECs have been previously reported to have approximately 400,000 IGF1R/cell and 40,000 IR/cell [30]. Furthermore, according to the updated version of Human Protein Atlas (https://www.proteinatlas.org/) [60], HepG2 and HeLa cells have been reported to express 21.9 and 27.5 IGF1R transcripts per million (TPM), respectively and 15.9 and 1.9 IR TPM respectively [61]. Higher IR levels could preserve insulin-stimulated Akt and Erk1 phosphorylation by increasing the number of activated receptors and signal intensity. The high relative IR expression levels in HepG2 cells may therefore explain why
A769662 had no effect on attenuation of insulin signalling in this cell line, whereas in HUVECs and HAECs, which have lower IR expression levels, there was such a marked effect of A769662.

It is unlikely that the differential effects of A769662 in the different cell types can be explained by differences in AMPK isoform expression, due to the selectivity of A769662 and compound 991 [31]. Both compounds would be expected to activate AMPK complexes containing β1, and complexes containing AMPKβ1 were found to contribute ~60% of the total cellular AMPK activity in HAECs. It has previously been reported that HepG2 cells principally express AMPKβ1, whereas HeLa cells express both AMPKβ1 and AMPKβ2 [36]. This further indicates that the inhibition of insulin signalling in ECs by A769662 is an AMPK-independent effect and unrelated to differential actions on specific pools of AMPK within ECs, as all the cell types investigated express abundant AMPKβ1 levels. As AMPK-independent effects of A769662, including inhibition of 26S proteasome activity in MEFs, voltage-gated Na+ channels in rat neurons and the Na+/K+ ATPase in L6 cells [26,28,29] have been reported previously, inhibition of insulin signalling in ECs may similarly be considered AMPK-independent. In addition, A769662 was recently reported to promote vasorelaxation in rabbit and rat arteries by reducing cytosolic Ca2+ levels, by an endothelium-dependent yet AMPK-independent manner [62].

In conclusion, A769662 decreases insulin-stimulated NO synthesis and Akt Ser473 phosphorylation in HUVECs and HAECs in a manner likely to be independent of AMPK. Furthermore, A769662 decreases insulin-stimulated Erk1/2 phosphorylation in a manner that is AMPK-independent in MEFs and HAECs. Taken together, these data demonstrate that caution should be exercised when interpreting data obtained using A769662 as a tool in cultured human endothelial cells.

4. Materials and Methods

4.1. Materials

Cryopreserved HUVECs, HAECs and MV2 medium were purchased from Promocell (Heidelberg, Germany). SV40-immortalised wild-type and AMPKα1 and AMPKα2 knock-out MEFs were kindly provided by Dr. B. Viollet (Institut Cochin, Paris, France) and have been described previously [33]. HeLa and HepG2 cells were obtained from ATCC (Manassas, VA, USA). IGF1, VEGF, SBI-0206965 and porcine insulin were purchased from Sigma Aldrich (St. Louis, MO, USA). AICAR was purchased from Toronto Research Chemicals Inc. (Ontario, ON, Canada). Compound 991 was synthesised by MRC Technology. A769662 and mouse anti-β-tubulin (#11307) antibodies were purchased from Abcam (Cambridge, UK). Rabbit anti-phospho-Akt Thr308 (#13038), anti-phospho-Akt Ser473 (#4058), anti-ERK1/2 (#9102), anti-phospho-ACC Ser79 (#3661), anti-α-tubulin (#2144) and mouse anti-Akt (#2920) and anti-phospho-p44/42 Erk1/2 (Thr202/Tyr204) (#9106) antibodies were from New England Biolabs UK (Hitchin, UK). Sheep anti-AMPKα1, anti-AMPKα2, anti-AMPKβ1 and anti-AMPKβ2 antibodies used for immunoprecipitation of AMPK complexes containing specific subunit isoforms were a kind gift from Professor D.G. Hardie (University of Dundee) and have been described previously [39,63,64]. IRdye680 or 800-labelled donkey anti-mouse IgG (#926-32212) and anti-rabbit IgG (#926-32213) antibodies were from LI-COR Biosciences (Lincoln, UK). Medium 199, RPMI 1640 and DMEM (4.5 g/L glucose) were from Life Technologies (Paisley, UK).

4.2. Cell Culture and Experimental Design

HAECs and HUVECs were cultured in MV2 medium supplemented with EC growth factor mix, 5% (v/v) serum (Promocell). HUVECs and HAECs were utilised between passages 3 and 6. MEFs and HeLa cells were cultured in DMEM supplemented with 10% (v/v) foetal calf serum. HepG2 cells were cultured in RPMI 1640 supplemented with 10% (v/v) foetal calf serum, 1 mM sodium pyruvate. Once cells reached 90–100% confluence, HUVECs/HAECs were incubated in serum-free Medium 199 and HeLa cells and HepG2 cells were incubated with serum-free DMEM for 2 h and then with AMPK activators prior to stimulation with insulin (1 μM), VEGF (10 ng/mL) or IGF1 (25 ng/mL). Cells were
placed on ice and washed with PBS prior to lysis in Triton X-100-based lysis buffer (50 mM Tris-HCl, pH 7.4 at 4 °C, 50 mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 250 mM mannitol, 1 mM DTT, 1 mM Na3VO4, 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/mL SBTI). Cell lysates were scraped into microcentrifuge tubes and incubated on ice for 20 min, centrifuged (5 min, 21,910 × g, 4 °C) and the subsequent supernatants stored at −20 °C. Lysate protein concentrations were determined using Bradford or BCA methods, as previously described [6,21].

4.3. SDS-Polyacrylamide Gel Electrophoresis and Immunoblotting

Cell lysate proteins were resolved by SDS-PAGE and immunoblotted with antibodies diluted in 50% (v/v) LI-COR blocking buffer in TBS containing 0.1% (v/v) Tween-20 as described previously [13]. Proteins were visualised using infrared dye-labelled secondary antibodies on a LI-COR Odyssey infrared imaging system and analysed using the ImageJ software for densitometric quantification of band intensity. In some cases, indicated in the figure legends, immunoblots were stripped in 0.2 M NaOH for 10 min, washed multiple times with Tris-buffered saline (TBS) until the pH returned to 7.2, and then blocked in TBS supplemented with 5% (w/v) milk powder prior to probing with primary antibodies. In all other cases, immunoblots for phospho- and total protein levels of ACC, Akt and Erk1/2 were obtained on immunoblots conducted concurrently in parallel.

4.4. NO Assay

HAECs and HUVECs were cultured in 6-well plates until 100% confluent and serum-starved for 2 h in Medium 199 and then in the presence of Krebs-Ringer-Hepes (KRH) buffer for 20 min. The medium was replaced and cells incubated in the presence or absence of stimuli in KRH for a further 15–20 min. Samples of medium (50 µL) were taken at different intervals and 200 µL methanol added to each. Samples were centrifuged (21,910 × g, 4 °C, 20 min), and supernatants were stored at −20 °C. NO concentration was determined using a Sievers 280A NO Meter (Sievers, Boulder, CO, USA) as described previously [21].

4.5. AMPK Assay

AMPK specific isoforms were immunoprecipitated from HAECs using sheep anti-AMPKα1, anti-AMPKα2 [63], anti-AMPKβ1 [39] or anti-AMPKβ2 [64] antibodies bound to protein G-Sepharose (1 µg antibody and 5 µL packed volume protein G-Sepharose/immunoprecipitation) in IP buffer (50 mM Tris-HCl (pH 7.4 at 4 °C), 150 mM NaCl, 50 mM NaF, 5 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 1% (v/v) glycerol, 1 mM DTT, 0.1 mM benzamidine, 1 mM PMSF, 5 µg/mL SBTI, 1 mM Na3VO4). Immunoprecipitates were then washed into HBD buffer (50 mM HEPES-NaOH (pH 7.4), 0.02% (v/v) Brij-35, 1 mM DTT) and assayed for AMPK activity using SAMS substrate peptide as described previously [12,35].

4.6. Statistical Analysis

All data is expressed as a relative change (mean ± SEM) from control baseline or normalised to group of reference for each experiment. Prism software (GraphPad Software, San Diego, CA, USA) was used to perform one or two-way ANOVA (with Tukey’s or Dunnett’s post hoc multiple comparison tests), where appropriate, using p < 0.05 as significant.

Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/19/12/3886/s1.

Author Contributions: Conceptualisation, A.S. and I.P.S.; Methodology, A.S. and I.P.S.; Investigation, A.S., S.J.M., J.M.G. and I.P.S.; Validation, A.S., S.J.M. and J.M.G.; Formal Analysis, A.S., S.J.M. and I.P.S.; Writing—Original Draft Preparation, A.S. and I.P.S.; Writing—Review & Editing, I.P.S., T.M.P. and G.S.B.; Supervision, I.P.S.; Funding Acquisition I.P.S. and T.M.P. All listed authors approved the final version of the manuscript.

Funding: This work was supported by the British Heart Foundation studentship (FS/14/61/31284 to A.S.), a British Heart Foundation Project Grant (PG/13/82/30483 to I.P.S. and T.M.P.) and a Diabetes UK equipment grant (BDA11/0004309 to I.P.S. and T.M.P.).
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References
1. Zhao, Y.; Vanhoutte, P.M.; Leung, S.W.S. Vascular nitric oxide: Beyond eNOS. *J. Pharmacol. Sci.* 2015, 12, 83–94. [CrossRef] [PubMed]
2. Manning, B.D.; Toker, A. AKT/PKB Signaling: Navigating the Network. *Cell* 2017, 169, 381–405. [CrossRef] [PubMed]
3. Jiang, Z.Y.; He, Z.; King, B.L.; Kuroki, T.; Opland, D.M.; Suzuma, K.; Suzuma, I.; Ueki, K.; Kulkarni, R.N.; Kahn, C.R. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. *J. Biol. Chem.* 2003, 278, 31964–31971. [CrossRef] [PubMed]
4. Takahashi, S.; Mendelsohn, M.E. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt. Calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. *J. Biol. Chem.* 2003, 278, 30821–30827. [CrossRef] [PubMed]
5. Michell, B.J.; Griffiths, J.E.; Mitchelhill, K.I.; Rodriguez-Crespo, I.; Tiganis, T.; Bozinovski, S.; Montellano, P.R.O.; Kemp, B.E.; Pearson, R.B. The Akt kinase signals directly to endothelial nitric oxide synthase. *Curr. Biol.* 1999, 9, 845–848. [CrossRef] [PubMed]
6. Ritchie, S.A.; Kohlhaas, C.F.; Boyd, A.R.; Yalla, K.C.; Walsh, K.; Connell, J.M.; Salt, I.P. Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at serine-615 contributes to nitric oxide synthesis. *Biochem. J.* 2010, 426, 85–90. [CrossRef] [PubMed]
7. Reynolds, L.J.; Credeur, D.P.; Manrique, C.; Padilla, J.; Fadel, P.J.; Thyfault, J.P. Obesity, type 2 diabetes, and impaired insulin-stimulated blood flow: Role of skeletal muscle NO synthase and endothelin-1. *J. Appl. Physiol.* 2017, 122, 38–47. [CrossRef] [PubMed]
8. Tabit, C.E.; Chung, W.B.; Vita, J.A. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. *Rev. Endocr. Metab. Disord.* 2010, 11, 61–74. [CrossRef] [PubMed]
9. Day, E.A.; Ford, R.J.; Steinberg, G.R. AMPK as a Therapeutic Target for Treating Metabolic Diseases. *Trends Endocrinol. MeTab.* 2017, 28, 545–560. [CrossRef]
10. Salt, I.P.; Hardie, D.G. AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway with Key Roles in the Cardiovascular System. *Circ. Res.* 2017, 120, 1825–1841. [CrossRef]
11. Mancini, S.J.; White, A.D.; Bijland, S.; Rutherford, C.; Graham, D.; Richter, E.A.; Viollet, B.; Touyz, R.M.; Palmer, T.M.; Salt, I.P. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. *Mol. Cell. Endocrinol.* 2017, 440, 44–56. [CrossRef] [PubMed]
12. Mancini, S.J.; Boyd, D.; Katwan, O.J.; Strembicka, A.; Almabrouk, T.A.; Kennedy, S.; Palmer, T.M.; Salt, I.P. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and independent mechanisms. *Sci. Rep.* 2018, 8, 5276. [CrossRef] [PubMed]
13. Peyton, K.J.; Liu, X.M.; Yu, Y.; Yates, B.; Durante, W. Activation of AMP-Activated Protein Kinase Inhibits the Proliferation of Human Endothelial Cells. *J. Pharmacol. Exp. Ther.* 2012, 342, 827–834. [CrossRef] [PubMed]
14. Li, C.; Reif, M.M.; Craige, S.M.; Kant, S.; Keaney, J.F. Endothelial AMPK activation induces mitochondrial biogenesis and stress adaptation via eNOS-dependent mTORC1 signaling. *Nitric Oxide-Biol. Chem.* 2016, 55–56, 45–53. [CrossRef] [PubMed]
15. Ido, Y.; Carling, D.; Ruderman, N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: Inhibition by the AMP-activated protein kinase activation. *Diabetes* 2002, 51, 159–167. [CrossRef] [PubMed]
16. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.J.; et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. *Cell MeTab.* 2011, 13, 376–388. [CrossRef] [PubMed]
17. Ford, R.J.; Fullerton, M.D.; Pinkosky, S.L.; Day, E.A.; Scott, J.W.; Oakhill, J.S.; Bujak, A.L.; Smith, B.K.; Crane, J.D.; Blümer, R.M.; et al. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. *Biochem. J.* 2015, 468, 125–132. [CrossRef] [PubMed]

18. Mottillo, E.P.; Desjardins, E.M.; Crane, J.D.; Smith, B.K.; Green, A.E.; Ducommun, S.; Henriksen, T.I.; Rebalka, I.A.; Razi, A.; Sakamoto, K.; et al. Lack of Adipocyte AMPK Exacerbates Insulin Resistance and Hepatic Steatosis through Brown and Beige Adipose Tissue Function. *Cell Metab.* 2016, 24, 118–129. [CrossRef]

19. Boyle, J.G.; Logan, P.J.; Ewart, M.A.; Reihill, J.A.; Ritchie, S.A.; Connell, J.M.; Cleland, S.J.; Salt, I.P. Rosiglitazone Stimulates Nitric Oxide Synthesis in Human Aortic Endothelial Cells via AMP-activated Protein Kinase. *J. Biol. Chem.* 2008, 283, 11210–11217. [CrossRef]

20. Davis, B.J.; Xie, Z.; Viollet, B.; Zou, M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric-oxide synthesis in human aortic endothelial cells. *J. Biol. Chem.* 2003, 278, 31629–31639. [CrossRef] [PubMed]

21. Morrow, V.A.; Foufelle, F.; Connell, J.M.C.; Petrie, J.R.; Gould, G.W.; Salt, I.P. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. *J. Biol. Chem.* 2009, 284, H2721–H2735. [CrossRef]

22. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell Metab.* 2006, 3, 403–416. [CrossRef] [PubMed]

23. Bultot, L.; Jensen, T.E.; Lai, Y.C.; Madsen, A.L.; ColloMET, C.; Kvikklyte, S.; Deak, M.; Yavari, A.; Foretz, M.; Ghaffari, S.; et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* 2016, 311, E706–E719. [CrossRef] [PubMed]

24. Ducommun, S.; Ford, R.J.; Bultot, L.; Deak, M.; Bertrand, L.; Kemp, B.E.; Steinberg, G.R.; Sakamoto, K. Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. *Am. J. Physiol. Endocrinol. Metab.* 2014, 306, E688–E696. [CrossRef] [PubMed]

25. Asiedu, M.N.; Han, C.; Dib-Hajj, S.D.; Waxman, S.G.; Price, T.J.; Dussor, G. The AMPK activator A769662 blocks voltage-gated sodium channels: Discovery of a novel pharmacophore with potential utility for analgesic development. *PloS ONE* 2017, 12, e0169882. [CrossRef] [PubMed]

26. Vlachaki Walker, J.M.; Robb, J.L.; Cruz, A.M.; Malhi, A.; Weightman Potter, P.G.; Ashford, M.L.; McCRIMMON, R.J.; Ellacott, K.L.; Beall, C. AMP-activated protein kinase (AMPK) activator A769662 increases intracellular calcium and ATP release from astrocytes in an AMPK-independent manner. *Diabetes Obes. Metab.* 2017, 19, 997–1005. [CrossRef]

27. Moreno, D.; Knecht, E.; Viollet, B.; Sanz, P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. *FEBS Lett.* 2008, 582, 2650–2654. [CrossRef]

28. Benziane, B.; Björnholm, M.; Lantier, L.; Viollet, B.; Zierath, J.R.; Chibalin, A.V. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na+K+-ATPase. *Am. J. Physiol. Cell Physiol.* 2009, 297, C1554–C1567. [CrossRef]

29. Zeng, G.; Quon, M.J. Insulin-stimulated production of nitric oxide is inhibited by Wortmannin: Direct measurement in vascular endothelial cells. *J. Clin. Invest.* 1996, 98, 894–898. [CrossRef]

30. Xiao, B.; Sanders, M.J.; Carmena, D.; Bright, N.J.; Haire, L.F.; Underwood, E.; Patel, B.R.; Heath, R.B.; Walker, P.A.; Hallen, S.; et al. Structural basis of AMPK regulation by small molecule activators. *Nat Commun.* 2013, 4, 1–17. [CrossRef] [PubMed]

31. Dite, T.A.; Langendorf, C.G.; Hoque, A.; Galic, S.; Rebello, R.J.; Ovens, A.J.; Lindqvist, L.M.; Ngoei, K.R.; Ling, N.X.; Furic, L.; et al. AMP-activated protein kinase selectively inhibited by the type II inhibitor SB1-202965. *J. Biol. Chem.* 2018, 293, 8874–8885. [CrossRef] [PubMed]

32. Jørgensen, S.B.; Viollet, B.; Andreelli, F.; Frosig, C.; Birk, J.B.; Schjerling, P.; Vaulont, S.; Richter, E.A.; Wojtaszewski, J.F. Knockout of the α2 but Not α1 5′-AMP-activated Protein Kinase Isoform Abolishes...
5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside but Not Contraction-induced Glucose Uptake in Skeletal Muscle. J. Biol. Chem. 2004, 279, 1070–1079. [CrossRef] [PubMed]

34. Reihill, J.A.; Ewart, M.A.; Salt, I.P. The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells. Vasc. Cell. 2011, 3, 9. [CrossRef] [PubMed]

35. Heathcote, H.R.; Mancini, S.J.; Strembitska, A.; Jamal, K.; Reihill, J.A.; Palmer, T.M.; Gould, G.W.; Salt, I.P. Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487. Biochem. J. 2016, 473, 4681–4697. [CrossRef] [PubMed]

36. Scott, J.W.; Galic, S.; Graham, K.L.; Foitzik, R.; Ling, N.X.; Dite, T.A.; Issa, S.M.; Langendorf, C.G.; Weng, Q.P.; Thomas, H.E.; et al. Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release. Chem. Biol. 2015, 22, 705–711. [CrossRef] [PubMed]

37. Lee, Y.S.; Kim, W.S.; Kim, K.H.; Yoon, M.J.; Cho, H.J.; Shen, Y.; Ye, J.M.; Lee, C.H.; Oh, W.K.; Kim, C.T.; et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55, 2256–2264. [CrossRef] [PubMed]

38. Zang, M.; Zuccollo, A.; Hou, X.; Nagata, D.; Walsh, K.; Herscovitz, H.; Brecher, P.; Ruderman, N.B.; Cohen, R.A. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 2004, 279, 47898–47905. [CrossRef]

39. Hawley, S.A.; Ross, F.A.; Chevtzoff, C.; Green, K.A.; Evans, A.; Fogarty, S.; Towler, M.C.; Brown, L.J.; Ogumbayo, O.A.; Evans, A.M.; et al. Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010, 11, 554–565. [CrossRef]

40. Liu, X.; Peyton, K.J.; Shebib, A.R.; Wang, H.; Korthuis, R.J.; Durante, W. Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H84–H93. [CrossRef]

41. Dang, Y.; Ling, S.; Duan, J.; Ma, J.; Ni, R.; Xu, J.W. Bavachalcone-Induced Manganese Superoxide Dismutase Expression through the AMP-Activated Protein Kinase Pathway in Human Endothelial Cells. Pharmacology 2015, 95, 105–110. [CrossRef] [PubMed]

42. Rutherford, C.; Speirs, C.; Williams, J.J.L.; Ewart, M.A.; Mancini, S.J.; Hawley, S.A.; Delles, C.; Violet, B.; Costa-Pereira, A.P.; Baillie, G.S.; et al. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci. Signal. 2016, 9, ral09. [CrossRef] [PubMed]

43. Kim, A.S.; Miller, E.J.; Wright, T.M.; Li, J.; Qi, D.; Atsina, K.; Zaha, V.; Sakamoto, K.; Young, L.H. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2011, 51, 24–32. [CrossRef] [PubMed]

44. Bradley, E.A.; Zhang, L.; Genders, A.J.; Richards, S.M.; Rattigan, S.; Keske, M.A. Enhancement of insulin-mediated rat muscle glucose uptake and microvascular perfusion by 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside. Cardiovasc. Diabetol. 2015, 14, 91. [CrossRef] [PubMed]

45. Liu, Z.; Jiang, C.; Zhang, J.; Liu, B.; Du, Q. Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. J. Diabetes 2016, 8, 324–335. [CrossRef]

46. Stahmann, N.; Woods, A.; Spengler, K.; Heslegrave, A.; Bauer, R.; Krause, S.; Viollet, B.; Carling, D.; Heller, R. Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J. Biol. Chem. 2010, 285, 10638–10652. [CrossRef]

47. Mount, P.F.; Hill, R.E.; Fraser, S.A.; Levidiotis, V.; Katsis, F.; Kemp, B.E.; Power, D.A. Acute renal ischemia rapidly activates the energy sensor AMPK but does not increase phosphorylation of eNOS-Ser1177. Am. J. Physiol. Physiol. 2005, 289, F1103–F1115. [CrossRef]

48. Montagnani, M.; Chen, H.; Barr, V.A.; Quon, M.J. Insulin-stimulated Activation of eNOS Is Independent of Ca2+ but Requires Phosphorylation by Akt at Ser1179. J. Biol. Chem. 2001, 276, 30392–30398. [CrossRef]

49. Van Heemst, D. Insulin, IGF-1 and longevity. Aging Dis. 2010, 1, 147–157. [CrossRef]

50. Varewijk, A.J.; Janssen, J.A. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr. Relat. Cancer 2012, 19, F63–F75. [CrossRef]

51. Cai, W.; Sakaguchi, M.; Kleinrieders, A.; Gonzalez-Del Pino, G.; Dreyfuss, J.M.; O’Neill, B.T.; Ramirez, A.K.; Pan, H.; Winnay, J.N.; Boucher, J.; et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat. Commun. 2017, 8, 14892. [CrossRef] [PubMed]
52. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling—In control of vascular function. *Nat. Rev. Mol. Cell. Biol.* 2006, 7, 359–371. [CrossRef] [PubMed]

53. King, G.L.; Park, K.; Li, Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: The 2015 Edwin Bierman Award Lecture. *Diabetes* 2016, 65, 1462–1471. [CrossRef] [PubMed]

54. Göransson, O.; McBride, A.; Hawley, S.A.; Ross, F.A.; Shpiro, N.; Foretz, M.; Violet, B.; Hardie, D.G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J. Biol. Chem.* 2007, 282, 32549–32560. [CrossRef] [PubMed]

55. Choudhury, Y.; Yang, Z.; Ahmad, I.; Nixon, C.; Salt, I.P.; Leung, H.Y. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. *Oncoscience* 2014, 1, 446. [CrossRef] [PubMed]

56. Göransson, O.; McBride, A.; Hawley, S.A.; Ross, F.A.; Shpiro, N.; Foretz, M.; Violet, B.; Hardie, D.G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J. Biol. Chem.* 2007, 282, 32549–32560. [CrossRef] [PubMed]

57. Green, C.J.; Pedersen, M.; Pedersen, B.K.; Scheele, C. Elevated NF-κB activation is conserved in human myocytes cultured from obese type 2 diabetic patients and attenuated by AMP-activated protein kinase. *Diabetes* 2011, 60, 2810–2819. [CrossRef]

58. Timmermans, A.D.; Balteau, M.; Gélinas, R.; Renguet, E.; Ginion, A.; de Meester, C.; Sakamoto, K.; Balligand, J.L.; Bontemps, F.; Vanoverschelde, J.L.; et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake. *Am. J. Physiol. Heart Circ. Physiol.* 2014, 306, H1619–H1630. [CrossRef] [PubMed]

59. Olianas, M.C.; Dedoni, S.; Onali, P. Signalling pathways mediating phosphorylation and inactivation of glycogen synthase kinase-3β by the recombinant human δ-opioid receptor stably expressed in Chinese hamster ovary cells. *Neuropharmacology* 2011, 60, 1326–1336. [CrossRef]

60. Human Protein Atlas. Available online: https://www.proteinatlas.org/ENSG00000017427-IGF1/cell (accessed on 6 June 2018).

61. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based Human Protein Atlas. *Nat. Biotechnol.* 2010, 28, 1248–1250. [CrossRef]

62. Huang, Y.; Smith, C.A.; Chen, G.; Sharma, B.; Miner, A.S.; Barbee, R.W.; Ratz, P.H. The AMP-Dependent Protein Kinase (AMPK) activator A-769662 causes arterial relaxation by reducing cytosolic free calcium independently of an increase in AMPK phosphorylation. *Front. Pharmacol.* 2017, 8, 1–14. [CrossRef] [PubMed]

63. Woods, A.; Salt, I.; Scott, J.; Hardie, D.G.; Carling, D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. *FEBS Lett.* 1996, 397, 347–351. [CrossRef]

64. Durante, P.E.; Mustard, K.J.; Park, S.H.; Winder, W.W.; Hardie, D.G. Effects of endurance training on activity and expression of AMP-activated protein kinase isoforms in rat muscles. *Am. J. Physiol. Endocrinol. Metab.* 2002, 283, E178–E186. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).